Author(s) Details:
Rajashri Namdev Kausdikar
Department of Pharmaceutical Chemistry, Appasaheb Birnale College of Pharmacy, Sangli, Maharashtra, India.
Manish S Kondawar
Department of Pharmaceutical Chemistry, Appasaheb Birnale College of Pharmacy, Sangli, Maharashtra, India.
Fahim J Sayyad
Department of Pharmaceutical Chemistry, Appasaheb Birnale College of Pharmacy, Sangli, Maharashtra, India.
This section is a part of the chapter: Mupirocin Emulgel: Formulation and Evaluation for the Management of Primary and Secondary Infections in Dry Skin Conditions
Mupirocin (MP), a topical antibiotic agent is effectively used for the treatment of primary and secondary skin infections. Mupirocin is produced by Pseudomonas fluorescens and has in vitro activity against a range of Gram-positive and some Gram-negative bacteria. However, Mupirocin also inhibits the growth of a number of pathogenic fungi in vitro, including a range of dermatophytes and pityrosporum. Mupirocin inhibits bacterial protein synthesis by binding to the enzyme, isoleucyl-t-RNA synthetase, which prevents the incorporation of isoleucine into proteins (Amrutiya et al., 2009, Pons-Guiraud, 2007).
How to Cite
Kausdikar, R. N. ., Kondawar, M. S. ., & Sayyad, F. J. . (2025). Mupirocin Emulgel: Formulation and Evaluation for the Management of Primary and Secondary Infections in Dry Skin Conditions. Pharmaceutical Science: New Insights and Developments Vol. 4, 62–76. https://doi.org/10.9734/bpi/psnid/v4/4713